Evidence map›Paper›PMID 29976668›Full record

ArticleJournal of virology2018

Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2.

Elena Heusinger, Katja Deppe, Paola Sette, Christian Krapp, Dorota Kmiec, Silvia F Kluge, Preston A Marx, Cristian Apetrei, Frank Kirchhoff, Daniel Sauter

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Elena HeusingerInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Katja DeppeInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Paola SetteDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Christian KrappInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Dorota KmiecInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Silvia F KlugeInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Preston A MarxTulane National Primate Research Center, Tulane University, Covington, Louisiana, USA.
Cristian ApetreiDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Daniel SauterInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany daniel.sauter@uni-ulm.de.
Universität Ulm · DEUniversity of Pittsburgh · USTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Animal Model for Testing SIV Latency Reversal StrategiesR01AI119346 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APETREI, CRISTIAN · 2015 to 2019
$3.4M
Pathogenesis of New SIVsm Lineages in Rhesus MacaquesR01AI065325 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APETREI, CRISTIAN · 2006 to 2009
$2.6M
NIAID NIH HHS R01 AI065325NIAID NIH HHS R01 AI119346NIH HHS P51 OD011104
6 · The paper itself

Abstract

The host restriction factor tetherin inhibits virion release from infected cells and poses a significant barrier to successful zoonotic transmission of primate lentiviruses to humans. While most simian immunodeficiency viruses (SIV), including the direct precursors of human immunodeficiency virus type 1 (HIV-1) and HIV-2, use their Nef protein to counteract tetherin in their natural hosts, they fail to antagonize the human tetherin ortholog. Pandemic HIV-1 group M and epidemic group O strains overcame this hurdle by adapting their Vpu and Nef proteins, respectively, whereas HIV-2 group A uses its envelope (Env) glycoprotein to counteract human tetherin. Whether or how the remaining eight groups of HIV-2 antagonize this antiviral factor has remained unclear. Here, we show that Nef proteins from diverse groups of HIV-2 do not or only modestly antagonize human tetherin, while their ability to downmodulate CD3 and CD4 is highly conserved. Experiments in transfected cell lines and infected primary cells revealed that not only Env proteins of epidemic HIV-2 group A but also those of a circulating recombinant form (CRF01_AB) and rare groups F and I decrease surface expression of human tetherin and significantly enhance progeny virus release. Intriguingly, we found that many SIVsmm Envs also counteract human as well as smm tetherin. Thus, Env-mediated tetherin antagonism in different groups of HIV-2 presumably stems from a preadaptation of their SIVsmm precursors to humans. In summary, we identified a phenotypic trait of SIVsmm that may have facilitated its successful zoonotic transmission to humans and the emergence of HIV-2.

Indexed as

Antigens, CDBone Marrow Stromal Antigen 2CD3 ComplexCD4 Antigensenv Gene Products, Human Immunodeficiency VirusGene Products, nefGPI-Linked ProteinsHIV-2Host-Pathogen InteractionsHumansSimian Immunodeficiency VirusAntigens, CDBone Marrow Stromal Antigen 2BST2 protein, humanCD3 ComplexCD4 Antigensenv Gene Products, Human Immunodeficiency VirusGene Products, nefGPI-Linked ProteinsEnvHIV-2NefSIVsmmtetherin

Identifiers

PMID29976668
PMCPMC6146695
OpenAlexW2811354608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.